Company announcement - No. 47 / 2017
Total number of shares and voting rights in Zealand at September 30, 2017
Copenhagen, September 29, 2017 - In accordance with Section 10 of the Danish Statutory Order on Issuers' Disclosure Obligations, Zealand issues announcements regarding the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.
In Company announcement Nos. 43 / 2017 of September 1, 2017 and 46 / 2017 of September 22, 2017, Zealand announced an increase in its share capital after the exercise of employee warrants. Following these announcements, the table below lists the total number of shares and voting rights in Zealand at September 30, 2017:
| Date | Number of shares (nominal value of DKK 1 each) | Share capital (nominal value in DKK) | Number of voting rights |
| September 30, 2017 | 30,748,827 | 30,748,827 | 30,748,827 |
For further information, please contact:
Mats Blom, Executive Vice President and Chief Financial Officer Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com
About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases. Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Adlyxin® in the U.S. and as Lyxumia® in the rest of the world. Lixisenatide has been developed in a combination with basal insulin glargine (Lantus®) and is marketed as Soliqua® 100/33 in the U.S. and has been approved as Suliqua® in Europe and launched in the Netherlands. Zealand's clinical pipeline includes: dasiglucagon (single-dose rescue treatment) for acute, severe hypoglycemia (Phase 3); glepaglutide for short bowel syndrome (Phase 2 completed); dasiglucagon (multiple-dose version) intended for use in a dual-hormone artificial pancreas system to reduce the risk of hypoglycemia and better diabetes management (Phase 2) as well as for the treatment of congenital hyperinsulinism, and other earlier-stage clinical and preclinical peptide therapeutics. Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on Linked-in or Twitter @ZealandPharma.
Attachments:
